WE DO NOT SHIP TO RESIDENTIAL ADDRESSES. For pricing in CAD/AUD/NZD please contact us.

Recombinant Mouse Legumain/LGMN Protein (His Tag)(Active) - PKSM040307

Recombinant Mouse Legumain/LGMN Protein (His Tag)(Active) - PKSM040307

Regular price
$1,213.80
Regular price
Sale price
$1,213.80
Unit price
per 
Availability
Sold out

Recombinant Mouse Legumain/LGMN Protein (His Tag)(Active)

Size: 50μg

Catalogue Number: PKSM040307-50

Citations, Manuals and MSDS Available upon request.

Abbreviation: Legumain; LGMN

Target Symptom: Legumain; Lgmn; Asparaginyl endopeptidase; Protease cysteine 1; Prsc1; AEP

Target Species: Mouse

Expression Host: HEK293 Cells

Application: Enzyme

Fusion Tag: C-His

Accession: NP_035305.1

Background: The Mammalian Legumain, also known as LGMN, also called asparaginyl endopeptidase (AEP), is a cysteine protease belonging to peptidase family C13 with a strict specificity for hydrolysis of asparaginyl bonds. Known previously only from plants and invertebrates, Legumain is discovered as a lysosomal endopeptidase in mammals. Mammalian Legumain is a cysteine endopeptidase, inhibited by iodoacetamide and maleimides, but unaffected by compound E64. The Mammalian Legumain is involved in the processing of bacterial peptides and endogenous proteins for MHC class II presentation in the lysosomal/endosomal systems. Legumain has been observed to be highly expressed in several types of solid tumors. It was demonstrated in membrane-associated vesicles concentrated at the invadopodia of tumor cells and on cell surfaces where it colocalized with integrins. Legumain was demonstrated to activate progelatinase A. Cells overexpressing Legumain possessed increased migratory and invasive activity in vitro and adopted an invasive and metastatic phenotype in vivo, inferring significance of Legumain in tumor invasion and metastasis. In addition, Legumain is expressed in both murine and human atherosclerotic lesions. The macrophage-specific expression of Legumain in vivo and ability of Legumain to induce chemotaxis of monocytes and endothelial cells in vitro suggest that Legumain may play a functional role in atherogenesis.

Activity: Measured by its ability to cleave the fluorogenic peptide substrate, N-carbobenzyloxy-Ala-Ala-Asn-7-amido-4-methyl coumarin(Z-AAN-AMC). The specific activity is > 350 pmoles/min/μg. (Activation description: The enzyme achieves its activity under acidic pH)

Sequence: Val 18-Tyr 435

Purity: > 75 % as determined by reducing SDS-PAGE.

Formulation: Lyophilized from sterile 25mM Tris, 0.15M NaCl, 20% Glycerol, pH 7.5
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.

Reconstitution: Please refer to the printed manual for detailed information.

Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.

Calculated MW: 49.8 kDa

Observed MW: 55 kDa

Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.

Shipping: This product is provided as lyophilized powder which is shipped with ice packs.

Research Use Only